Evidence map›Paper›PMID 39460538›Full record

ReviewCNS neuroscience & therapeutics2024

The Gut Microbiota Modulates Neuroinflammation in Alzheimer's Disease: Elucidating Crucial Factors and Mechanistic Underpinnings.

Jianshe Yang, Junyi Liang, Niyuan Hu, Ningjuan He, Bin Liu, Guoliang Liu, Ying Qin

Abstract readReview
In one paragraph

Review in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. The effects ofIBRO neuroscience reports · 2026
    Article
  2. Glutamine metabolism in health and disease.Signal transduction and targeted therapy · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianshe YangHarbin Institute of Physical Education, Harbin, Heilongjiang Province, China.ORCID 0009-0003-0127-3334
Junyi LiangHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.ORCID 0009-0000-3011-5819
Niyuan HuHarbin Institute of Physical Education, Harbin, Heilongjiang Province, China.
Ningjuan HeHarbin Institute of Physical Education, Harbin, Heilongjiang Province, China.
Bin LiuHeilongjiang University of Traditional Chinese Medicine, Harbin, Heilongjiang Province, China.
Guoliang LiuHarbin Institute of Physical Education, Harbin, Heilongjiang Province, China.
Ying QinHarbin Institute of Physical Education, Harbin, Heilongjiang Province, China.

Funding

Innovative Research Project for Postgraduate Students of Heilongjiang University of Traditional Chinese Medicine 2024yjscx013
6 · The paper itself

Abstract

background and purposeAlzheimer's disease (AD) is characterized by progressive cognitive decline and neuronal loss, commonly linked to amyloid-β plaques, neurofibrillary tangles, and neuroinflammation. Recent research highlights the gut microbiota as a key player in modulating neuroinflammation, a critical pathological feature of AD. Understanding the role of the gut microbiota in this process is essential for uncovering new therapeutic avenues and gaining deeper insights into AD pathogenesis.

methodsThis review provides a comprehensive analysis of how gut microbiota influences neuroinflammation and glial cell function in AD. A systematic literature search was conducted, covering studies from 2014 to 2024, including reviews, clinical trials, and animal studies. Keywords such as "gut microbiota," "Alzheimer's disease," "neuroinflammation," and "blood-brain barrier" were used.

resultsDysbiosis, or the imbalance in gut microbiota composition, has been implicated in the modulation of key AD-related mechanisms, including neuroinflammation, blood-brain barrier integrity, and neurotransmitter regulation. These disruptions may accelerate the onset and progression of AD. Additionally, therapeutic strategies targeting gut microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation, show promise in modulating AD pathology.

conclusionsThe gut microbiota is a pivotal factor in AD pathogenesis, influencing neuroinflammation and disease progression. Understanding the role of gut microbiota in AD opens avenues for innovative diagnostic, preventive, and therapeutic strategies.

Indexed as

Alzheimer DiseaseGastrointestinal MicrobiomeNeuroinflammatory DiseasesAnimalsBlood-Brain BarrierDysbiosisFecal Microbiota TransplantationHumansProbioticsAlzheimer's diseasedysbiosisgut microbiotamicrobiota–gut–brain axismicroglianeuroinflammation

Identifiers

PMID39460538
PMCPMC11512114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.